OBJECTIVE: To investigate associations between health-related quality of life (HRQoL), as assessed using the multidimensional quality of life-HIV (MQOL-HIV) questionnaire, and adherence to antiretroviral treatment in HIV-infected subjects. DESIGN: Multicentre cross-sectional study in three institutional tertiary hospitals in northwest Spain. PATIENTS AND METHODS: The MQOL-HIV was completed by 235 HIV-infected adults undergoing antiretroviral treatment. Adherence to antiretroviral therapy was assessed by using patient's self-report. Information about sociodemographic characteristics and clinical variables was also collected. RESULTS: Good adherence (> or = 95% of prescribed pills correctly taken) was reported by 131 patients (55.7%). Univariate analyses indicated that the sociodemographic and clinical variables associated with adherence were age, educational level, income, employment, home stability, transmission route, history of previous antiretroviral therapy, and number of prescribed pills/day. Subscales of MQOL-HIV associated with adherence were mental health, cognitive functioning, financial status, medical care, partner intimacy, and (in men only) sexual functioning. Stepwise logistic regression showed that good adherence was more frequent in patients aged > 40 years (odds ratio, OR: 2.50; 95% confidence interval, CI: 1.15-5.61) and in patients with high cognitive functioning (OR: 2.26; 95% CI: 1.19-4.30). Conversely, poor adherence was more frequent in patients without stable home (OR: 2.96; 95% CI: 1.39-6.32), in patients required to take 14 or more pills/day (OR: 2.17; 95% CI: 1.18-4.28), in patients with low financial status (OR: 3.42; 95% CI: 1.57-7.45), and in patients reporting low medical care (OR: 2.07; 95% CI: 1.07-3.98). CONCLUSIONS: HRQoL dimensions, notably cognitive functioning, financial status and medical care, are closely associated with antiretroviral therapy adherence.
OBJECTIVE: To investigate associations between health-related quality of life (HRQoL), as assessed using the multidimensional quality of life-HIV (MQOL-HIV) questionnaire, and adherence to antiretroviral treatment in HIV-infected subjects. DESIGN: Multicentre cross-sectional study in three institutional tertiary hospitals in northwest Spain. PATIENTS AND METHODS: The MQOL-HIV was completed by 235 HIV-infected adults undergoing antiretroviral treatment. Adherence to antiretroviral therapy was assessed by using patient's self-report. Information about sociodemographic characteristics and clinical variables was also collected. RESULTS: Good adherence (> or = 95% of prescribed pills correctly taken) was reported by 131 patients (55.7%). Univariate analyses indicated that the sociodemographic and clinical variables associated with adherence were age, educational level, income, employment, home stability, transmission route, history of previous antiretroviral therapy, and number of prescribed pills/day. Subscales of MQOL-HIV associated with adherence were mental health, cognitive functioning, financial status, medical care, partner intimacy, and (in men only) sexual functioning. Stepwise logistic regression showed that good adherence was more frequent in patients aged > 40 years (odds ratio, OR: 2.50; 95% confidence interval, CI: 1.15-5.61) and in patients with high cognitive functioning (OR: 2.26; 95% CI: 1.19-4.30). Conversely, poor adherence was more frequent in patients without stable home (OR: 2.96; 95% CI: 1.39-6.32), in patients required to take 14 or more pills/day (OR: 2.17; 95% CI: 1.18-4.28), in patients with low financial status (OR: 3.42; 95% CI: 1.57-7.45), and in patients reporting low medical care (OR: 2.07; 95% CI: 1.07-3.98). CONCLUSIONS: HRQoL dimensions, notably cognitive functioning, financial status and medical care, are closely associated with antiretroviral therapy adherence.
Authors: K Maher; N Klimas; M A Fletcher; V Cohen; C M Maggio; J Triplett; R Valenzuela; G Dickinson Journal: J Acquir Immune Defic Syndr Date: 1999-12-01 Impact factor: 3.731
Authors: D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: G Pialoux; F Raffi; F Brun-Vezinet; V Meiffrédy; P Flandre; J A Gastaut; P Dellamonica; P Yeni; J F Delfraissy; J P Aboulker Journal: N Engl J Med Date: 1998-10-29 Impact factor: 91.245
Authors: M-J Milloy; Thomas Kerr; David R Bangsberg; Jane Buxton; Surita Parashar; Silvia Guillemi; Julio Montaner; Evan Wood Journal: AIDS Patient Care STDS Date: 2011-11-22 Impact factor: 5.078
Authors: Jane Loh; Mary Clare Kennedy; Evan Wood; Thomas Kerr; Brandon Marshall; Surita Parashar; Julio Montaner; M-J Milloy Journal: AIDS Care Date: 2016-06-01
Authors: Jonathan A Shaffer; John L P Thompson; Bin Cheng; Siqin Ye; Gregory Y H Lip; Douglas L Mann; Ralph L Sacco; Patrick M Pullicino; Ronald S Freudenberger; Susan Graham; J P Mohr; Arthur J Labovitz; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; Marco R Di Tullio; Shunichi Homma Journal: Int J Cardiol Date: 2014-12-15 Impact factor: 4.164
Authors: Surita Parashar; Alexis K Palmer; Nadia O'Brien; Keith Chan; Anya Shen; Suzy Coulter; Julio S G Montaner; Robert S Hogg Journal: AIDS Behav Date: 2011-11
Authors: Julio Lopez-Bastida; Juan Oliva-Moreno; Lilisbeth Perestelo-Perez; Pedro Serrano-Aguilar Journal: BMC Health Serv Res Date: 2009-03-30 Impact factor: 2.655